BioLineRx Ltd. (BLRX)

BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of $11.30 million. The enterprise value is $6.67 million.

Market Cap	11.30M
Enterprise Value	6.67M

Important Dates

The next estimated earnings date is Tuesday, May 27, 2025, before market open.

Earnings Date	May 27, 2025
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 2.23 billion shares outstanding. The number of shares has increased by 24.37% in one year.

Current Share Class	n/a
Shares Outstanding	2.23B
Shares Change (YoY)	+24.37%
Shares Change (QoQ)	+9.05%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.13B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.39
Forward PS	n/a
PB Ratio	0.84
P/TBV Ratio	3.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.23
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.76, with a Debt / Equity ratio of 1.12.

Current Ratio	1.76
Quick Ratio	1.52
Debt / Equity	1.12
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.11

Financial Efficiency

Return on equity (ROE) is -69.11% and return on invested capital (ROIC) is -44.90%.

Return on Equity (ROE)	-69.11%
Return on Assets (ROA)	-23.28%
Return on Invested Capital (ROIC)	-44.90%
Return on Capital Employed (ROCE)	-81.50%
Revenue Per Employee	$1.03M
Profits Per Employee	-$329,321
Employee Count	28
Asset Turnover	0.56
Inventory Turnover	3.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -87.77% in the last 52 weeks. The beta is 0.86, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	-87.77%
50-Day Moving Average	3.08
200-Day Moving Average	12.63
Relative Strength Index (RSI)	52.01
Average Volume (20 Days)	18,024

Short Selling Information

Short Interest	198,765
Short Previous Month	217,240
Short % of Shares Out	5.85%
Short % of Float	n/a
Short Ratio (days to cover)	7.45

Income Statement

In the last 12 months, BioLineRx had revenue of $28.94 million and -$9.22 million in losses. Loss per share was -$0.01.

Revenue	28.94M
Gross Profit	19.68M
Operating Income	-19.15M
Pretax Income	-49.15M
Net Income	-9.22M
EBITDA	-15.70M
EBIT	-19.15M
Loss Per Share	-$0.01

Balance Sheet

The company has $19.56 million in cash and $15.04 million in debt, giving a net cash position of $4.52 million or $0.00 per share.

Cash & Cash Equivalents	19.56M
Total Debt	15.04M
Net Cash	4.52M
Net Cash Per Share	$0.00
Equity (Book Value)	13.46M
Book Value Per Share	0.01
Working Capital	11.70M

Cash Flow

In the last 12 months, operating cash flow was -$43.87 million and capital expenditures -$53,000, giving a free cash flow of -$43.93 million.

Operating Cash Flow	-43.87M
Capital Expenditures	-53,000
Free Cash Flow	-43.93M
FCF Per Share	-$0.02

Margins

Gross margin is 67.99%, with operating and profit margins of -66.18% and -31.86%.

Gross Margin	67.99%
Operating Margin	-66.18%
Pretax Margin	-31.86%
Profit Margin	-31.86%
EBITDA Margin	-54.25%
EBIT Margin	-66.18%
FCF Margin	n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.37%
Shareholder Yield	-24.37%
Earnings Yield	-81.63%
FCF Yield	-388.87%

Analyst Forecast

The average price target for BioLineRx is $26.00, which is 715.05% higher than the current price. The consensus rating is "Buy".

Price Target	$26.00
Price Target Difference	715.05%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on January 30, 2025. It was a reverse split with a ratio of 0.025:1.

Last Split Date	Jan 30, 2025
Split Type	Reverse
Split Ratio	0.025:1

Scores

BioLineRx has an Altman Z-Score of -13.48 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.48
Piotroski F-Score	3